Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
CONCLUSION: In this real-life experience, all of the 21 PrOD-treated RT recipients reached SVR12. Tac or Csa serum levels were maintained within the normal range with close monitoring. PrOD regime can be successfully and safely used in RT recipients with HCV infection with close follow-up.
PMID: 31418413 [PubMed - in process]
Source: The Turkish Journal of Gastroenterology - Category: Gastroenterology Authors: Danış N, Toz H, Ünal N, Yılmaz M, Turan İ, Günşar F, Karasu Z, Ersöz G, Özkahya M, Akarca US Tags: Turk J Gastroenterol Source Type: research
More News: Anemia | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis C | Kidney Transplant | Kidney Transplantation | Norvir | Prograf | Restasis | Study | Tacrolimus | Transplant Surgery | Transplants | Turkey Health | Urology & Nephrology | Virology